CLAUDE SMITH: Open Payments
NPI 1619929676 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,190 in 19 payments from 12 companies in 2025. Trend: 2023 $588 · 2024 $727 · 2025 $4,190
Debt forgiveness: $3,602Food & beverage: $588
| Company | Payments | Amount |
|---|---|---|
| Neuronetics, Inc. | 1 | $3,602 |
| Teva Pharmaceuticals USA, Inc. | 6 | $211 |
| Supernus Pharmaceuticals, Inc. | 1 | $119 |
| Janssen Pharmaceuticals, Inc | 3 | $98 |
| ABBVIE INC. | 1 | $28 |
| Alkermes, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Almatica Pharma LLC | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
Products named: NEUROSTAR TMS THERAPY SYSTEM, UZEDY, Qelbree, INVEGA SUSTENNA, VRAYLAR, LYBALVI, ABILIFY ASIMTUFII, LOREEV XR.
Industry payments across MD — which companies pay providers there.
